Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $29.96 in the last session, up 1.80% from day before closing price of $29.43. In other words, the price has increased by $1.80 from its previous closing price. On the day, 1.84 million shares were traded. ARQT stock price reached its highest trading level at $30.18 during the session, while it also had its lowest trading level at $29.28.
Ratios:
We take a closer look at ARQT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Matsuda Masaru sold 1,657 shares for $30.23 per share. The transaction valued at 50,091 led to the insider holds 150,641 shares of the business.
Welgus Howard G. sold 10,000 shares of ARQT for $302,133 on Dec 01 ’25. The Director now owns 79,744 shares after completing the transaction at $30.21 per share. On Dec 01 ’25, another insider, Howard Welgus, who serves as the Director of the company, bought 10,000 shares for $30.21 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 3669865984 and an Enterprise Value of 3592572160. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.54 while its Price-to-Book (P/B) ratio in mrq is 22.80. Its current Enterprise Value per Revenue stands at 11.3 whereas that against EBITDA is -108.246.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.72, which has changed by 1.3907392 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $31.27, while it has fallen to a 52-week low of $11.13. The 50-Day Moving Average of the stock is 27.91%, while the 200-Day Moving Average is calculated to be 76.76%.
Shares Statistics:
According to the various share statistics, ARQT traded on average about 2.34M shares per day over the past 3-months and 2431160 shares per day over the past 10 days. A total of 120.29M shares are outstanding, with a floating share count of 107.62M. Insiders hold about 12.14% of the company’s shares, while institutions hold 96.52% stake in the company. Shares short for ARQT as of 1763078400 were 13717750 with a Short Ratio of 5.85, compared to 1760486400 on 14276026. Therefore, it implies a Short% of Shares Outstanding of 13717750 and a Short% of Float of 13.76.
Earnings Estimates
. The current assessment of Arcutis Biotherapeutics Inc (ARQT) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.03, with high estimates of $0.12 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.15 and -$0.31 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is $0.45, with 7.0 analysts recommending between $0.78 and $0.25.
Revenue Estimates
According to 6 analysts,. The current quarter’s revenue is expected to be $109.83M. It ranges from a high estimate of $112.6M to a low estimate of $107M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $71.36MFor the next quarter, 6 analysts are estimating revenue of $98.23M. There is a high estimate of $102.31M for the next quarter, whereas the lowest estimate is $94.6M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $361.3M, while the lowest revenue estimate was $353.6M, resulting in an average revenue estimate of $357.45M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $467.32M in the next fiscal year. The high estimate is $470.1M and the low estimate is $462M.
